StockNews.AI
LYEL
StockNews.AI
2 days

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

1. Lyell discussed LYL314 data at ICML 2025, highlighting promising clinical results. 2. LYL314 targets CD19 and CD20, enhancing responses in large B-cell lymphoma. 3. Management will present at H.C. Wainwright Series on June 25, 2025. 4. LYL314 has RMAT and Fast Track designations, indicating its developmental significance. 5. Current trial focuses on relapsed/refractory LBCL, signaling potential market opportunities.

6 mins saved
Full Article

FAQ

Why Bullish?

LYL314's promising data and FDA designations increase investor confidence. Historical examples show similar advancements led to strong price gains for biotech stocks.

How important is it?

The announcement of positive clinical data and FDA designations is critical for LYEL’s valuation.

Why Long Term?

The ongoing pivotal trial's outcomes will inform long-term market potential. Historical drug approvals in oncology have led to sustained stock growth.

Related Companies

CRSPBLCMZIOP
June 23, 2025 17:00 ET  | Source: Lyell Immunopharma, Inc SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will participate in the H.C. Wainwright “HCW@Home” Series taking place virtually on Wednesday, June 25, 2025, at 12:00 PM ET. The discussion will highlight the positive new clinical data recently presented in an oral session at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, on LYL314, Lyell’s lead product candidate, and the emerging landscape of next-generation dual targeting chimeric antigen receptor (CAR) T-cell therapy for patients with large B-cell lymphoma (LBCL). LYL314 is an autologous dual-targeting CD19/CD20 CAR T-cell product candidate with Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration (FDA) that is in pivotal-stage development for patients with relapsed and/or refractory LBCL. LYL314 is designed to increase complete response rates and prolong the duration of the responses as compared to the approved CD19‑targeted CAR T-cell therapies for the treatment of LBCL. Fireside chat details are as follows: Lyell Speakers: Lynn Seely, MD, President and Chief Executive Officer and Charlie Newton, Chief Financial OfficerDate and Time: Wednesday, June 25, 2025, 12:00 PM to 1:00 PM ETWebcast Link: Register here A live webcast of the presentation can be accessed through the Investors section of the Company's website at www.lyell.com. Following the live presentation, a replay of the webcast will be available on the Company's website. About Lyell Immunopharma, Inc. Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. Lyell’s LyFE Manufacturing Center™ has commercial launch capability and can manufacture more than 1,200 CAR T-cell doses at full capacity. To learn more, please visit www.lyell.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell management’s attendance and presentation of clinical data on LYL314 at an investor conference; the potential clinical benefits and therapeutic potential of LYL314 for patients with relapsed and/or refractory LBCL; the potential benefits, if any, from the RMAT and Fast Track designations from the FDA for the treatment of patients with relapsed and/or refractory LBCL in the third- or later-line setting; and expectations around enrollment and timing of Lyell’s ongoing single-arm pivotal PiNACLE trial evaluating LYL314 in patients in the third- or later-line setting. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties described under the heading “Risk Factors” in Lyell’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission on May 13, 2025. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law. Contact: Ellen RoseSenior Vice President, Communications and Investor Relationserose@lyell.com

Related News